1) Functional psychogenic symptoms and 2) Topic of the month: Stroke and stroke care. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Michael Sharpe about his paper on guided self-help for functional (psychogenic) symptoms. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Melkersson-Rosenthal syndrome. In the next part of the podcast Dr. Brett Kissela interviews Drs. Ralph Sacco and Larry Goldstein about prevention of stroke part 2. Over the subsequent three weeks, Dr. Kissela will interview Drs. Bo Norrving, Mark Eckman and Tom Brott about other aspects of stroke and stroke care. The participants had nothing to disclose except Drs. Sharpe, Burns, Fugate, Kissela, Sacco and Goldstein.Dr. Sharpe serves as an Associate Editor for the Journal of Psychosomatic Research and on the editorial boards of General Hospital Psychiatry, Psychological Medicine, and Psychosomatics; serves as an independent medical advisor to AEGON Insurance; receives publishing royalties from Oxford University Press, Wiley-Blackwell and Churchill Livingstone and serves on a DSM5 work group for the American Psychiatric Association; is a member of Council of the Academy of Psychosomatic Medicine and receives research support from the Medical Research Council UK and Cancer Research UK.Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela has served on the scientific advisory board for for Allergan, Inc.; receives honoraria from Allergan, Inc; receives research support from the NIH; and gave expert testimony in medico legal cases related to stroke. Dr. Sacco serves on a data safety monitoring board indirectly sponsored by Pfizer Inc; serves on the editorial boards of Stroke and Neuroepidemiology; and receives research support from the NIH and the Evelyn McKnight Brain Institute. Dr. Goldstein is a consultant for Allergan, Inc. and Merck Serono; serves on the Steering Committee, SPARCL trial, is a consultant and speaker at meetings in which the SPARCL trial is discussed, Pfizer Inc serves on the Neurology Executive Committee, RESPECT Trial (AGA Medical) Clinical Oversight Committee, and ACT-1 trial (Abbott); and received research support from the RESPECT Trial Site (AGA Medical).